1. Home
  2. WVE vs WLFC Comparison

WVE vs WLFC Comparison

Compare WVE & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • WLFC
  • Stock Information
  • Founded
  • WVE 2012
  • WLFC 1985
  • Country
  • WVE Singapore
  • WLFC United States
  • Employees
  • WVE N/A
  • WLFC N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • WLFC Industrial Specialties
  • Sector
  • WVE Health Care
  • WLFC Consumer Discretionary
  • Exchange
  • WVE Nasdaq
  • WLFC Nasdaq
  • Market Cap
  • WVE 915.6M
  • WLFC 1.0B
  • IPO Year
  • WVE 2015
  • WLFC 1996
  • Fundamental
  • Price
  • WVE $8.31
  • WLFC $126.00
  • Analyst Decision
  • WVE Strong Buy
  • WLFC
  • Analyst Count
  • WVE 14
  • WLFC 0
  • Target Price
  • WVE $20.79
  • WLFC N/A
  • AVG Volume (30 Days)
  • WVE 3.6M
  • WLFC 49.8K
  • Earning Date
  • WVE 11-07-2025
  • WLFC 11-04-2025
  • Dividend Yield
  • WVE N/A
  • WLFC 0.79%
  • EPS Growth
  • WVE N/A
  • WLFC 30.03
  • EPS
  • WVE N/A
  • WLFC 16.84
  • Revenue
  • WVE $93,946,000.00
  • WLFC $637,163,000.00
  • Revenue This Year
  • WVE N/A
  • WLFC $16.17
  • Revenue Next Year
  • WVE $6.26
  • WLFC $4.88
  • P/E Ratio
  • WVE N/A
  • WLFC $7.49
  • Revenue Growth
  • WVE N/A
  • WLFC 32.40
  • 52 Week Low
  • WVE $5.28
  • WLFC $124.90
  • 52 Week High
  • WVE $16.74
  • WLFC $235.43
  • Technical
  • Relative Strength Index (RSI)
  • WVE 56.37
  • WLFC 34.20
  • Support Level
  • WVE $8.18
  • WLFC $129.39
  • Resistance Level
  • WVE $9.75
  • WLFC $133.82
  • Average True Range (ATR)
  • WVE 0.64
  • WLFC 3.48
  • MACD
  • WVE 0.14
  • WLFC 0.17
  • Stochastic Oscillator
  • WVE 48.94
  • WLFC 10.36

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

Share on Social Networks: